Published in Surgery on February 01, 1974
L-dopa in hepatic coma. Ann Surg (1976) 0.92
Treatment of acute hepatic encephalopathy with L-dopa. Postgrad Med J (1977) 0.88
The Human Experience with Intravenous Levodopa. Front Pharmacol (2016) 0.75
Management of hepatic encephalopathy. Br Med J (Clin Res Ed) (1981) 0.75
Orthostatic stability with intravenous levodopa. PeerJ (2015) 0.75
Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med (1991) 2.05
Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet (1975) 1.66
Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. Clin Exp Immunol (1975) 1.59
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology (1998) 1.50
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol (1998) 1.46
High frequency of hemorrhagic strokes in Jerusalem during the Persian Gulf War. Neurology (1992) 1.43
Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature (1975) 1.43
An association between multiple sclerosis and type I diabetes mellitus. J Neurol (1992) 1.42
Lack of hemispheric localizing value of the palmomental reflex. Neurology (2005) 1.40
Serum Cu/Zn superoxide dismutase activity is reduced in sporadic amyotrophic lateral sclerosis patients. J Neurol Sci (1996) 1.38
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol (1997) 1.22
Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol (1986) 1.20
Antibodies to oligodendroglia in patients with multiple sclerosis. N Engl J Med (1977) 1.20
Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol (1984) 1.16
Inosiplex in the treatment of subacute sclerosing panencephalitis. Arch Neurol (1979) 1.16
Guillain-Barré syndrome after epidural anesthesia: direct nerve root damage may trigger disease. Neurology (1985) 1.16
Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. Arch Neurol (2001) 1.13
Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest (1991) 1.10
Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs. J Exp Med (1975) 1.10
Radioimmunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients. Isr J Med Sci (1978) 1.09
Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. Eur J Immunol (1994) 1.08
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler (2010) 1.07
Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol (1999) 1.06
Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis. Proc Natl Acad Sci U S A (1975) 1.03
Spontaneous tendon ruptures in patients treated by chronic hemodialysis. Clin Orthop Relat Res (1977) 1.02
HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol (1999) 1.02
Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol (1975) 1.01
Association of MS with thyroid disorders. Neurology (1999) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Regulated expression of proenkephalin A in normal lymphocytes. J Immunol (1989) 0.99
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol (2001) 0.99
Complete unilateral ophthalmoplegia as the presenting manifestation of Waldenström's macroglobulinemia. Neurology (1990) 0.99
Ictal hemiparesis. Eur Neurol (1982) 0.98
Sensory peripheral neuropathy of vitamin B12 deficiency: a primary demyelinating disease? J Neurol (1988) 0.98
Neurologic manifestations of progressive systemic sclerosis. Arch Neurol (1992) 0.98
Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. Ann Neurol (1991) 0.96
Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest (1993) 0.95
A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol (1998) 0.95
Neurological features as presenting manifestations of brucellosis. Eur Neurol (1977) 0.95
Cytokeratin expression in human thymus: immunohistochemical mapping. Cell Tissue Res (1995) 0.94
Electrophysiological examinations of the visual system in multiple sclerosis. J Neurol Sci (1973) 0.94
Cognitive dysfunction following thalamic stroke: a study of 16 cases and review of the literature. J Neurol Sci (2000) 0.93
Parkinsonism and hyperthyroidism. Eur Neurol (1974) 0.93
Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol (1986) 0.93
The bronchodilator effect of salbutamol administered by IPPB to patients with asthma. A controlled comparison with isoproterenol and placebo. Chest (1972) 0.92
Living polymerization and block copolymerization of alpha-olefins by an amine bis(phenolate) titanium catalyst. Chem Commun (Camb) (2001) 0.91
Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol (1992) 0.91
Stimulation of tumor necrosis factor-alpha production by mycoplasmas and inhibition by dexamethasone in cultured astrocytes. Brain Res (1993) 0.91
Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler (2003) 0.90
Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology (1996) 0.90
Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J Neuroimmunol (1994) 0.90
Antiacetylcholine receptor antibody in neonatal myasthenia gravis. Am J Dis Child (1981) 0.89
[Solitary metastatic involvement of the spleen in squamous cell carcinoma of the cervix]. Harefuah (1977) 0.89
Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol (1984) 0.89
Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis. Proc Natl Acad Sci U S A (1996) 0.89
Treatment of acute hepatic encephalopathy with L-dopa. Postgrad Med J (1977) 0.88
Cell-mediated immunity to neural antigens in idiopathic polyneuritis and myeloradiculitis. Clinical-immunologic classification of several autoimmune demyelinating disorders. Neurology (1975) 0.88
Neurologic manifestations in patients with mixed cryoglobulinemia. Neurology (1974) 0.88
Suppressive effect of pregnancy on the development of experimental allergic encephalomyelitis in rabbits. Am J Reprod Immunol (1984) 0.87
Neuritogenic and encephalitogenic properties of the peripheral nerve basic proteins. J Neuropathol Exp Neurol (1975) 0.87
Acetoacetate and D-(-)-beta-hydroxybutyrate as precursors for sterol synthesis by calf oligodendrocytes in suspension culture: extramitochondrial pathway for acetoacetate metabolism. J Neurochem (1979) 0.86
Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment. J Neurol (1986) 0.86
Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis. Mult Scler (2003) 0.86
Expression of alpha-smooth muscle actin in murine bone marrow stromal cells. Blood (1991) 0.86
Evaluation of the effect of stress on the blood--brain barrier: critical role of the brain perfusion time. Brain Res (2001) 0.85
Antibodies to galactocerebroside bind to oligodendroglia in suspension culture. J Neurol Sci (1979) 0.85
Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler (1999) 0.84
Myasthenia gravis in the elderly. J Am Geriatr Soc (1976) 0.84
Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT). Clin Exp Immunol (1995) 0.84
Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol (1994) 0.84
Changes in lymphocyte subsets in myasthenia gravis: correlation with level of antibodies to acetylcholine receptor and age of patient. Neurology (1992) 0.83
Adult-onset Niemann-Pick type C disease. Clinical, biochemical, and genetic study. Arch Neurol (1997) 0.83
In vitro synthesis of antibodies to acetylcholine receptor by Epstein-Barr virus-stimulated B-lymphocytes derived from patients with myasthenia gravis. J Neuroimmunol (1989) 0.83
Binding of peptides of the human acetylcholine receptor alpha-subunit to HLA class II of patients with myasthenia gravis. Hum Immunol (1995) 0.83
Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci (1999) 0.83
Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor. Neurology (1997) 0.83
Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. Perspect Biol Med (1978) 0.83
Immunosuppression of experimental autoimmune myasthenia gravis by hydrocortisone and azathioprine. J Immunol (1976) 0.83
Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report. J Neurol Sci (1977) 0.83
Immunosuppression of experimental autoimmune myasthenia gravis by azathioprine. II. Evaluation of immunological mechanism. J Immunol (1977) 0.82
Prevention of experimental autoimmune myasthenia gravis in rats by fetal alpha-fetoprotein-rich fractions. Tumour Biol (1984) 0.82
Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J Neuroimmunol (1997) 0.82
Fulminant subacute sclerosing panencephalitis in association with pregnancy. Arch Neurol (1988) 0.82
Mast cell activity in experimental allergic encephalomyelitis. Mol Chem Neuropathol (1991) 0.82
Paroxysmal choreoathetosis as a presenting symptom in idiopathic hypoparathyroidism. J Neurol Neurosurg Psychiatry (1977) 0.82
Significance in neonatal myasthenia gravis of inhibitory effect of amniotic fluid on binding of antibodies to acetylcholine receptor. Lancet (1980) 0.82
Detection of 14-3-3 protein in the CSF of genetic Creutzfeldt-Jakob disease. Neurology (1997) 0.82
Development of experimental allergic encephalomyelitis during steroid administration. Outcome of neurological immune-mediated disorders under immunosuppressive therapy. Isr J Med Sci (1991) 0.82
Evidence for the involvement of the central adrenergic system in the febrile response induced by interleukin-1 in rats. J Neuroimmunol (1989) 0.81
[Clinical trial of copolymer 1 in multiple sclerosis]. Harefuah (1989) 0.81
The autoimmune features of acute transverse myelopathy. Ann Neurol (1977) 0.81
Expression of biochemical properties of oligodendrocytes in oligodendrocyte x glioma cell hybrids proliferating in vitro. Exp Cell Res (1981) 0.81
Evidence for the genetic role of human leukocyte antigens in low frequency DRB1*1501 multiple sclerosis patients in Israel. Mult Scler (1999) 0.80
Exacerbation of myasthenia gravis during the menstrual period. J Neurol Sci (1998) 0.80
Dopamine receptors on isolated membranes of rat lymphocytes. J Neurosci Res (1987) 0.80
Evidence for the involvement of the central adrenergic system in interleukin 1-induced adrenocortical response. Neuropharmacology (1989) 0.80
Multiunit electrical activity in conscious rats during an immune response. Brain Behav Immun (1987) 0.80